GlassScriptPhysician profile
Saurabh Lalan
NPI 1679833917
$14,689.40
in general payments reported to CMS, 2019-2025
48 companies · $893 in 2025
The $893 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,508 · 2020: $4,017 · 2021: $2,474 · 2022: $1,443 · 2023: $1,245 · 2024: $1,111 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,248.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $3,145.70 | 2020-2025 | |
| Abbvie INC. | $1,577.26 | 2021-2025 | |
| Emd Serono, INC. | $979.22 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $923.59 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $816.94 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Medtronic USA, INC. | $683.28 | 2019 | |
| Neurelis, INC. | $572.80 | 2021-2025 | Valtoco |
| Allergan, INC. | $561.27 | 2019-2022 | |
| Livanova USA, INC. | $498.23 | 2019 | |
| Eisai INC. | $496.83 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $451.59 | 2019-2025 | |
| Amgen INC. | $442.11 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $397.18 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $305.27 | 2019-2021 | |
| Biogen, INC. | $284.24 | 2019-2024 | Vumerity, Tysabri |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Lalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.